American biopharmaceutical company: Ligand Pharmaceuticals (LGND) (1987)

Ligand Pharmaceuticals (NASDAQ:LGND) was founded in 1987 and is headquartered in La Jolla, California, USA, with 116 full-time employees. It is a professional biotechnology and biopharmaceutical company .

Ligand Pharmaceuticals Logo

Ligand Pharmaceuticals (LGND):

Ligand’s internal product development projects include the glucagon receptor antagonist program, the oral human granulocyte colony stimulating factor program, the LTP platform, kinase inhibitors, HepDirect HCV inhibitors, etc. LGND is developing a combination of treatments for a series of diseases for patients, including hepatitis, multiple myeloma, muscle contraction, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis And osteoporosis.

Ligand Pharmaceuticals has reached cooperation agreements with GlaxoSmithKline , Amgen , Merck , Pfizer , Baxter International and Eli Lilly.

Ligand Pharmaceuticals (LGND) product:

  • Promacta-used in dentistry to increase the number of platelets in the blood
  • Kyprolis-for the treatment of multiple myeloma
  • Bazedoxifene-for the treatment of postmenopausal osteoporosis
  • Captisol-enabled Noxafil-IV-posaconazole preparation for intravenous injection

The later development plan of Ligand includes:

  • Captisol-enabled Melphalan IV
  • MK-8931 β-secretase inhibitor
  • SAGE-547 with CAPTISOL function
  • Sparsentan
  • CAPTISOL function delafloxacin-IV
  • CAPTISOL function carbamazepine-IV inhibitor IRAK4
  • LTP technology and omega-3 fatty acids, biological treatment platform,
  • Topiramate IV with CAPTISOL function
  • Lasoxifene
  • Captisol function lamotrigine IV
Notify of
Inline Feedbacks
View all Intels

Mobile advertising company: Voltari Corporation (VLTC) (2001)

Biopharmaceutical company: Alexion Pharmaceuticals (ALXN) (1992)